Out of the Lab: Operationalizing Cell and Gene Therapy
The 2 AM Audit Reality: Ex-FDA Regulators on CDMO Oversight, Night Shift Sins, and Data Integrity
Why do processes that look clean on paper collapse during an FDA inspection? In this episode of Out of the Lab , host Nico Crudele sits down with ex-FDA auditors DeVaughn Edwards (GMP specialist) and Elvia Cervantes (GCP specialist) to break down the most common and preventable compliance disasters in cell and gene therapy. From night-shift compliance breakdowns and paper-only CDMO audits to data manipulation and informal quality decisions, DeVaughn and Elvia share unvarnished insights from their time inside the agency and in the field. Key Takeaways: You Can't Outsource Liability: Why delegating manufacturing to a CDMO or clinical monitoring to a CRO does not clear a sponsor's regulatory responsibility. The "Boots on the Ground" Mandate: Why paper questionnaires fail vendor qualification and how unmonitored night shifts breed compliance failures. Building Code vs. Blueprint: The cost of bringing Quality teams in midstream rather than from project inception. Data Integrity Realities: What actual record destruction and email-based decision-making signal to FDA investigators. Modern Audit Readiness: How remote regulatory assessments (RRAs), 1-day audits, and AI tools like ELSA are changing FDA oversight. Timestamps / Show Notes: 00:01:16 – The cost of involving Quality teams too late in development. 00:05:29 – Qualifying CDMOs: Why "boots on the ground" beat paper questionnaires. 00:09:08 – The 2 AM reality check: Night shift compliance breakdowns. 00:14:00 – Modern audit readiness, 1-day inspections, and FDA’s ELSA system. 00:24:43 – Data integrity red flags: Document destruction and pressure-driven cover-ups. 00:41:33 – Operational silos: When administrative assistants make escalation decisions. 00:47:32 – What an effective CAPA actually looks like. 01:05:15 – Inspecting emails and server migrations as regulatory liabilities.
